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A ctivity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model
Sir, Nisin, a lanthionine-containing peptide from L actococcus lactis, is used as a food preservative because of its activity against spoilage bacteria. Like other cationic peptides, nisin interacts with the cell membrane and induces pore formation. 1 Because of the increasing resistance of pathogenic bacteria to antibiotics, we are evaluating the potential use of nisin, and of variant peptides, as antimicrobial agents for human use.
Nisin was obtained from A plin & Barrett, Ltd, Beaminster, U K. O ther antimicrobial agents were supplied by Sigma Chemical Co., St Louis, MO , U SA . Clinical isolates of Streptococcus pneum oniae from the U SA and E u r o p e were kindly provided by Dr J. D . Knudsen, Statens Seruminstitut, Copenhagen, Denmark. MICs were determined by broth microdilution 2 in cation adjusted Mueller-H inton broth (D ifco, D etroit, MI, U SA ) with 5% fetal bovine serum (Sigma). Nisin dilutions were made in 0.2% bovine serum albumin (BSA ; Sigma) to prevent adsorption to plastic microtitre trays.
Swiss-Webster mice (Taconic Farms, G ermantown, NY, U SA ) weighing approximately 20 g were infected intraperitoneally, as described previously, 3 with 10 2 -10 3 cfu of S. pneum oniae Felton, approximately ten-fold the inoculum that reproducibly killed all untreated animals within 48 h. Five or six mice per group received antimicrobial agents intravenously (in 0.1 mL 5% dextrose for injection) or subcutaneously (0.2 mL), within 10 min of infection and, in some cases, 5 h later. Serum levels of nisin were assayed, using seven mice for each time point, by an agar diffusion method with M icrococcus luteus A TCC 9341 as indicator strain. Sample and standard dilutions were in 10% mouse serum. The limit of detection was 0.45 mg nisin/L serum.
A nimal experiments were conducted at New York Medical College, Valhalla, NY, U SA . A ll procedures were approved by the Institutional A nimal Care and U se Committee.
The MIC of nisin was 0.25 mg/L for the isolates tested, including human isolates with varying susceptibilities to penicillin (Table) . For the strain used in the infection model the nisin MIC was 0.06 mg/L. A n intravenous two-treatment nisin regimen of 0.16 mg/kg/treatment (total dose 0.31 mg/kg) protected 100% of the mice and 80% were protected by 0.63 mg/kg in a single iv dose or in two sc treatments (Table) . Vancomycin at 1.25 mg/kg/dose protected 80% of the mice.
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Five minutes after an iv dose of 20 mg/kg, the nisin concentration in serum was approximately 50 mg/L and declined with an apparent half-life of elimination of 0.9 h. Nisin was not detectable after 3 h.
Nisin showed excellent in-vitro activity against clinical isolates of S. pneum oniae, including penicillin-resistant and -intermediate strains, some of which were resistant to the other antimicrobial agents tested, with the exception of vancomycin. Nisin is rapidly bactericidal for S. pneum oniae clinical isolates at concentrations 1 mg/L (A . Tomasz, personal communication) and against staphylococci and enterococci at concentrations near the MIC (unpublished data). R apid bactericidal activity against susceptible organisms is a characteristic of cationic peptides and is related to their mechanism of action. 1 A lthough nisin and vancomycin had similar MIC for S. pneum oniae, including the strain used in the infection model, nisin was 8-16 times more active in a two-dose iv regimen in mice. A s nisin had a serum half-life in mice of only 0.9 h, it is not surprising that two doses were needed for optimal activity, as previously reported for vancomycin. 3 Low blood and tissue levels of nisin appear to be sufficient to prevent the death of mice infected with S. pneum oniae Felton, perhaps because of nisin's rapid bactericidal action.
Vancomycin is an alternative therapy for serious infections with multiply resistant S. pneum oniae and the first-line treatment for methicillin-resistant staphylococcal infections. R esistance to vancomycin in enterococci is increasing and there have been recent reports of S. aureus with intermediate resistance to the drug. 4 New therapies for G ram-positive infections are needed. E ukaryotic and synthetic antimicrobial peptides are under investigation as topical agents and as potential treatments for G ramnegative sepsis.
1 O ur data suggest that there may be a role for peptides such as nisin in the treatment of systemic disease. In addition to nisin itself, we are investigating variant molecules, produced by genetic engineering, which may have improved characteristics such as greater solubility or a better pharmacokinetic profile.
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Some of these data were presented at the Ninety-Seventh 1,2 In-vitro sensitivity results have thus far indicated a potential clinical role in the treatment of community-acquired respiratory tract infection. 3, 4 The mean peak plasma concentration (T max 1 h) after a 600 mg oral dose has been reported to be around 4 mg/L, with a steady state trough concentration of 1.0 mg/L. A standard dose of 400 mg once daily has been proposed for moxifloxacin.
5
A s with all new drug therapies, it is important to have a reliable assay to optimize therapy, study clinical pharmacokinetics and investigate any possible drug interactions. We have therefore developed a simple H PLC assay. The stationary phase was Spherisorb S5 C8 in a stainless steel column, 100 4.6 mm heated to 50°C (Waters Ltd, Watford, U K). The mobile phase was 0.16% ortho-phosphoric acid, adjusted to pH 3 with tetrabutylammonium hydroxide; 50 mL of acetonitrile was
